Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
230 studies found for:    Multiple System Atrophy
Show Display Options
Rank Status Study
21 Active, not recruiting Defining Phenotypes of Movement Disorders :Parkinson's Plus Disorders, PD,Essential Tremor, (ET),Cortical Basal Degeneration, (CBD),Multiple Systems Atrophy (MSA), Magnetoencephalography
Conditions: Essential Tremor;   Multiple System Atrophy;   Corticobasal Degeneration;   Supranuclear Palsy, Progressive
Intervention:
22 Active, not recruiting Norepinephrine Transporter Blockade as a Pathological Biomarker in Neurogenic Orthostatic Hypotension
Conditions: Orthostatic Hypotension;   Pure Autonomic Failure;   Multiple System Atrophy;   Parkinson's Disease
Intervention:
23 Recruiting Progression Rate of MSA Under EGCG Supplementation as Anti-Aggregation-Approach
Condition: Multiple System Atrophy
Interventions: Drug: EGCG as putative neuroprotective agent;   Drug: Placebo
24 Recruiting Water and Sudafed in Autonomic Failure
Conditions: Shy-Drager Syndrome;   Multiple System Atrophy
Interventions: Drug: Pseudoephedrine + 480 ml water;   Drug: Pseudoephedrine + 50 ml water;   Other: Placebo + 480 ml water (optional);   Other: Placebo + 50 ml water (optional)
25 Recruiting Study Assessing Safety and Therapeutic Activity of AFFITOPE® PD01A and PD03A in Patients With Early MSA
Conditions: Multiple System Atrophy;   Neurodegenerative Diseases
Interventions: Biological: AFFITOPE® PD01A + Adjuvant;   Biological: AFFITOPE® PD03A + Adjuvant;   Biological: Adjuvant without active component
26 Completed
Has Results
Open-Label Clinical Study of Droxidopa in Patients With Neurogenic Orthostatic Hypotension (NOH)
Conditions: Neurogenic Orthostatic Hypotension;   Non-Diabetic Autonomic Neuropathy;   Multiple System Atrophy;   Dopamine Beta Hydroxylase Deficiency
Interventions: Drug: Droxidopa;   Drug: Placebo
27 Recruiting Identifying Biomarkers of Parkinson's Disease Using Magnetic Resonance Imaging (MRI)
Conditions: Parkinson's Disease (PD);   Parkinsonism;   Progressive Supranuclear Palsy (PSP);   Multiple System Atrophy (MSA)
Intervention:
28 Completed Study About Efficacy and Safety to Treat Multi-System-Atrophy
Conditions: Multi-System-Atrophy;   Minocycline
Intervention: Drug: Minocyline
29 Recruiting Magnetic Resonance Spectroscopy in Autonomic Failure
Conditions: Pure Autonomic Failure;   Multiple System Atrophy
Intervention: Procedure: Magnetic Resonance Spectroscopy Imaging
30 Completed Increased Gut Permeability to Lipopolysaccharides (LPS) in Parkinson's Disease
Conditions: Parkinson's Disease;   Multiple System Atrophy
Intervention:
31 Unknown  Diagnostic and Prognostic Biomarkers in Parkinson Disease
Conditions: Parkinson Disease;   Multiple System Atrophy;   Progressive Supranuclear Palsy
Intervention:
32 Completed Analysis of the Enteric Nervous System Using Colonic Biopsies
Conditions: Parkinson's Disease;   Multiple System Atrophy;   Progressive Supranuclear Palsy
Intervention: Procedure: colonoscopy or rectosigmoidoscopy
33 Completed Research of Biomarkers in Parkinson Disease
Conditions: Parkinson Disease;   Multiple System Atrophy;   Progressive Supranuclear Palsy;   Huntington Disease;   Dystonia;   Diffuse Lewy Body Disease
Intervention:
34 Recruiting The Role of Endothelin in the Supine Hypertension of Autonomic Failure
Conditions: Hypertension;   Pure Autonomic Failure;   Multiple System Atrophy
Interventions: Drug: BQ123;   Drug: Bq123;   Drug: Saline
35 Recruiting Contribution of Angiotensin II to Supine Hypertension in Autonomic Failure
Conditions: Hypertension;   Pure Autonomic Failure;   Multiple System Atrophy
Interventions: Drug: Losartan;   Drug: Captopril;   Drug: Placebo
36 Completed Autonomic Failure Patients for RNA Blood Sampling
Conditions: Pure Autonomic Failure;   Multiple System Atrophy;   Parkinson's Plus Syndromes
Intervention:
37 Enrolling by invitation Botulinum A Toxin in Patients With Parkinson's Disease
Conditions: Parkinson's Disease;   Multiple System Atrophy;   Detrusor Overactivity
Intervention: Drug: Intravesical injection of Botulinum A toxin
38 Completed Droxidopa in Treating Patients With Neurogenic Hypotension
Conditions: Shy-Drager Syndrome;   Orthostatic Hypotension
Intervention: Drug: droxidopa
39 Terminated
Has Results
Augmenting Effects of L-DOPS With Carbidopa and Entacapone
Conditions: Parkinson Disease;   Multiple System Atrophy;   Autonomic Nervous System Diseases
Interventions: Drug: Droxidopa;   Drug: Carbidopa;   Drug: Entacapone
40 Active, not recruiting Nebivolol in the Supine Hypertension of Autonomic Failure
Conditions: Hypertension;   Pure Autonomic Failure;   Multiple System Atrophy
Interventions: Drug: Placebo;   Drug: Nebivolol 5 mg;   Drug: metoprolol tartrate 50 mg;   Drug: Sildenafil25 mg

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years